Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials

BACKGROUND: Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD concentrations and maintain them to allow a dosing...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Parkinsons Dis
Päätekijät: Nausieda, Paul A., Hsu, Ann, Elmer, Lawrence, Gil, Ramon A., Spiegel, Joerg, Singer, Carlos, Khanna, Sarita, Rubens, Robert, Kell, Sherron, Modi, Nishit B., Gupta, Suneel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: IOS Press 2015
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927929/
https://ncbi.nlm.nih.gov/pubmed/26444090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-150622
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia